Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1995

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Effects of a new oral contraceptive containing an antimineralocorticoid

progestogen, drospirenone, on the renin-aldosterone system, body weight,

blood pressure, glucose tolerance, and lipid metabolism.

AUTHORS

Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R

SOURCE

JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. 1995

ABSTRACT

The potential of a new oral contraceptive (OC) containing drospirenone (DRSP) to avert the moderate increases in

body weight and blood pressure often associated with use of existing combined OCs was investigated in a study of

four groups of 20 German women each. Group A received 30 mcg of ethinyl estradiol (EE) and 3 mg of DRSP, Group

B was administered 20 mcg of EE and 3 mg of DRSP, Group C received 15 mcg of EE and 3 mg of DRSP, and Group

D was given a standard OC containing 30 mcg of EE and 150 mcg of levonorgestrel. Between the pretreatment

cycle and the last (sixth) treatment cycle, mean body weight fell by 0.8-1.7 kg in Groups A, B, and C, but rose by 0.7

kg in Group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in Groups A, B, and C and rose by 1-2 mm

Hg in Group D. Renin substrate rose equally in all four groups, while plasma renin activity, plasma aldosterone, and

high density lipoprotein cholesterol rose significantly only in the three DRSP groups and serum triglyceride levels

were significantly higher in Group D than in the three DRSP groups. Glucose tolerance increases were similar in all

four groups. Finally, all groups--but especially Group A--experienced good cycle control and there were no serious

side effects. These findings suggest that a combined OC containing DRSP may be especially beneficial for women

who have a tendency to gain weight or experience a rise in blood pressure while taking OCs. (PubHealth.info

Document ID: CONT2T 2565-06)

PubHealth.info NOTE: The author(s) of this article titled, "Effects of a new oral contraceptive containing an

antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure,

glucose tolerance, and lipid metabolism.", is(are) Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R.

The source of this article is "JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. 1995 Jun;80(6):1816-

21.". This article was published in 1995 in English language(s). (PubHealth.info® Document ID: CONT2T 2565-06.

All rights reserved with PubHealth.info) PIN: 7565

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.